Regeneron: Catching Another Wind
Source: SeekingAlpha
2026-04-27 10:20:40 ET
Our last article about Regeneron ( REGN ) seems awkwardly timed in hindsight, given we called for even more upside from their all-time high when not a month later they entered a slow-but-steep selloff, no doubt exacerbated by the onslaught of issues around approval delays, political pressure around drug pricing, and the exogenous market shock of the US tariff announcements:
Read the full article on Seeking Alpha
For further details see:
Regeneron: Catching Another Wind
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
0.65% G/L:
$626.15 Last:
428,713 Volume:
$628.07 Open:
REGN Latest News
June 04, 2026 07:00:00 am
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
May 28, 2026 04:00:00 pm
Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
May 25, 2026 11:31:00 am
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
May 22, 2026 07:00:00 am
Otarmeni(TM) (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
